Inflammasome

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(Eine dazwischenliegende Version von einem Benutzer wird nicht angezeigt)
Zeile 1: Zeile 1:
 
{{up|PHA Biologicals}}
 
{{up|PHA Biologicals}}
 +
{{qt|Colchicine}}
  
−
 
−
colchicine as inh. of the inflammosome
 
−
 
−
{{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
 
−
{{tp|p=32251729|t=ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design |pdf=|usr=}}
 
−
{{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}}
 
−
{{tp|p=32380315|t=2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
 
−
{{tp|p=32472681|t=2020. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.|pdf=|usr=007}}
 
−
{{tp|p=32445400|t=2020. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?|pdf=|usr=007}}
 
−
{{tp|p=32511763|t=2020. Colchicine and COVID-19.|pdf=|usr=007}}
 
−
{{tp|p=32503853|t=2020. COVID-19 infection in a patient with FMF: does colchicine have a protective effect?|pdf=|usr=007}}
 
−
{{tp|p=32461554|t=2020. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.|pdf=|usr=008}}
 
−
{{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
 
−
{{tp|p=32426001|t=2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.|pdf=|usr=009}}
 
−
{{tp|p=32584431|t=2020. Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.|pdf=|usr=010}}
 
−
{{tp|p=32492478|t=2020. Treating COVID-19 with colchicine in community healthcare setting.|pdf=|usr=011}}
 
−
{{tp|p=32564213|t=2020. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.|pdf=|usr=010}}
 
−
{{tp|p=32564212|t=2020. Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?"|pdf=|usr=010}}
 
−
{{tp|p=32556936|t=2020. Colchicine as a possible therapeutic option in COVID-19 infection.|pdf=|usr=010}}
 
−
{{tp|p=32394215|t=2020. Colchicine may not be effective in COVID-19 infection; it may even be harmful?|pdf=|usr=011}}
 
−
{{tp|p=32579195|t=2020. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.|pdf=|usr=011}}
 
−
{{tp|p=32579190|t=2020. Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?|pdf=|usr=011}}
 
−
 
−
 
−
 
−
 
−
topic
 
 
{{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}}
 
{{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}}
 
{{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}}
 +
{{tp|p=32655582|t=2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.|pdf=|usr=015}}
 +
{{tp|p=32670297|t=2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.|pdf=|usr=014}}
 +
{{tp|p=32744716|t=2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.|pdf=|usr=017}}
 +
{{tp|p=32776354|t=2020. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.|pdf=|usr=017}}
 +
{{tp|p=32824985|t=2020. 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.|pdf=|usr=018}}
 +
{{tp|p=32841451|t=2020. Targeting NLRP3 Inflammasome in an Animal Model for SARS-CoV-2.|pdf=|usr=018}}
 +
{{tp|p=32965010|t=2020. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?|pdf=|usr=019}}
 +
{{tp|p=32980515|t=2020. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.|pdf=|usr=019}}
 +
{{tp|p=33066442|t=2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials.|pdf=|usr=021}}
 +
{{tp|p=33099890|t=2020. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?|pdf=|usr=020}}

Aktuelle Version vom 11. April 2021, 20:22 Uhr

PHA Biologicals
Colchicine
32493814 2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.


32574259 2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
32655582 2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.
32670297 2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
32744716 2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
32776354 2020. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
32824985 2020. 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.
32841451 2020. Targeting NLRP3 Inflammasome in an Animal Model for SARS-CoV-2.
32965010 2020. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
32980515 2020. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
33066442 2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials.
33099890 2020. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?

Von „http://coviki.org/cov/index.php?title=Inflammasome&oldid=677617“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis